★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Johnson & Johnson
JNJ · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Johnson & Johnson operates two segments: Innovative Medicine and MedTech. Innovative Medicine's moat is primarily legal - patents and other exclusivities that support pricing and share until loss of exclusivity, with pipeline execution as the reinvestment engine to offset patent cliffs; FY2025/Q1 2026 evidence still shows that STELARA biosimilar competition is a major live erosion vector. MedTech's moat is more demand- and relationship-driven - clinician training/workflow switching costs, reputation-based preference, and field sales/service support across procedure-centric categories, with the planned Orthopaedics separation now an execution item to monitor. Both segments face meaningful erosion vectors from competition and payer/government cost containment, keeping overall moat durability closer to medium than permanent.
Primary segment
Innovative Medicine
Market structure
Competitive
Market share
—
HHI: —
Coverage
2 segments · 6 tags
Updated 2026-06-03
Segments
Innovative Medicine
Branded prescription pharmaceuticals (biopharma)
Revenue
64.1%
Structure
Competitive
Pricing
moderate
Share
—
Peers
MedTech
Medical devices and procedure-based consumables (cardiovascular, orthopaedics, surgery, vision)
Revenue
35.9%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Moat Claims
Innovative Medicine
Branded prescription pharmaceuticals (biopharma)
Revenue/profit shares are derived from J&J FY2025 segment reporting: Innovative Medicine segment sales $60.401B and segment income before tax $22.266B (10-K filed 2026-02-11). Operating_profit_share uses J&J's reported segment income before tax as the closest disclosed segment profit measure. Q1 2026 review confirmed STELARA biosimilar pressure remained material, reducing worldwide Innovative Medicine operational sales growth by about 9.2 percentage points.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Patent and related exclusivities support pricing and share for key medicines; however, loss of exclusivity and patent challenges can rapidly erode sales via generics/biosimilars.
Erosion risks
- Patent cliffs / loss of exclusivity on top products, including ongoing STELARA biosimilar launches
- At-risk generic or biosimilar launches after adverse IP outcomes
- Government price-setting/controls and reimbursement pressure
Leading indicators
- Upcoming loss-of-exclusivity dates for top products
- Biosimilar approvals/launches vs key biologics
- Net price trends (gross-to-net) and payer formulary positioning
Counterarguments
- Payers can accelerate switching to lower-cost alternatives once biosimilars/generics are available
- Patent challenges can shorten expected exclusivity windows
Regulated Standards Pipe
Legal
Regulated Standards Pipe
Strength
Durability
Confidence
Evidence
Scale clinical/regulatory execution and pipeline replenishment create a continuing barrier; success depends on sustained R&D productivity and timely approvals.
Erosion risks
- Clinical failures or delays in late-stage programs
- Regulatory tightening or slower agency review timelines
- R&D productivity deterioration or weaker external innovation sourcing
Leading indicators
- Phase 3 readouts and major regulatory submissions/approvals
- R&D spend trajectory and mix (internal vs business development)
- New product launch cadence and early uptake
Counterarguments
- Large pharma peers and well-funded biotechs have similar regulatory capabilities
- Breakthrough innovation can come from smaller entrants and shift standards of care
MedTech
Medical devices and procedure-based consumables (cardiovascular, orthopaedics, surgery, vision)
Revenue/profit shares are derived from J&J FY2025 segment reporting: MedTech segment sales $33.792B and segment income before tax $4.113B (10-K filed 2026-02-11). Operating_profit_share uses J&J's reported segment income before tax as the closest disclosed segment profit measure. Q1 2026 review noted the planned Orthopaedics separation, targeted for completion 18-24 months after the October 2025 announcement.
Training Org Change Costs
Demand
Training Org Change Costs
Strength
Durability
Confidence
Evidence
In procedure-driven device categories (notably orthopaedics/trauma), surgeon training, familiarity, and associated hospital workflows/instrumentation create meaningful switching costs and loyalty effects.
Erosion risks
- Hospital procurement standardization can force brand switches
- New enabling technologies can reset clinician preferences
- Cost-containment and tendering can shift purchasing toward lowest price
Leading indicators
- Hospital win/loss rates in tenders and IDN/GPO contracts
- Clinician adoption and utilization metrics in key franchises
- Instrument/platform placements and associated procedure volumes
Counterarguments
- Hospitals can mandate switching when total cost savings are large
- Clinical evidence and innovation can move preferences quickly
Brand Trust
Demand
Brand Trust
Strength
Durability
Confidence
Evidence
Device markets often compete on perceived quality and reputation; J&J highlights reputation and customer service as key competitive factors and owns established brands (e.g., ACUVUE, TECNIS).
Erosion risks
- Product recalls or safety concerns damaging brand equity
- Clinical data favoring competitor devices
- Increasing price transparency reducing brand premium
Leading indicators
- Recall frequency and regulatory warning letters
- Clinician satisfaction/NPS (if disclosed) and repurchase rates
- Average selling price trends and mix shifts
Counterarguments
- In commoditized categories, purchasing can be primarily price-driven
- Reputation can be quickly impaired by quality issues
Service Field Network
Supply
Service Field Network
Strength
Durability
Confidence
Evidence
Field sales/service and in-hospital education support adoption and retention in complex device categories; training and demonstrations by sales reps are highlighted as part of market access dynamics in orthopaedic devices.
Erosion risks
- Provider consolidation reducing influence of field reps
- Remote/digital support commoditizing training services
- Cost cuts that weaken service responsiveness
Leading indicators
- Salesforce effectiveness and coverage in priority accounts
- Service response times and customer satisfaction metrics
- Share stability in franchises where in-procedure support is critical
Counterarguments
- Procurement bodies may prioritize total cost over service
- Competitors can replicate service models by hiring experienced reps
Evidence
Loss of patent exclusivity for a product often is followed by a substantial reduction in sales...
Directly supports the dependence on IP/exclusivity and the sharp revenue step-down after generic/biosimilar entry.
These rights are essential to the Company's businesses...
Positions patents/proprietary rights as essential to the business model.
the Company can lose a major portion of revenues... in a very short period of time.
Supports the cliff dynamics that both define and limit durability of the IP moat.
The process depends on many factors... achieve successful clinical trial results... obtain regulatory approvals...
Shows the centrality of large-scale clinical and regulatory execution for competitive success.
New products introduced within the past five years accounted for approximately 25% of 2025 sales.
Indicates meaningful contribution from newer products, consistent with ongoing pipeline commercialization.
Showing 5 of 11 sources.
Risks & Indicators
Erosion risks
- Patent cliffs / loss of exclusivity on top products, including ongoing STELARA biosimilar launches
- At-risk generic or biosimilar launches after adverse IP outcomes
- Government price-setting/controls and reimbursement pressure
- Clinical failures or delays in late-stage programs
- Regulatory tightening or slower agency review timelines
- R&D productivity deterioration or weaker external innovation sourcing
Leading indicators
- Upcoming loss-of-exclusivity dates for top products
- Biosimilar approvals/launches vs key biologics
- Net price trends (gross-to-net) and payer formulary positioning
- Share of sales from products launched in past 5 years
- Phase 3 readouts and major regulatory submissions/approvals
- R&D spend trajectory and mix (internal vs business development)
Research JNJ elsewhere
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the Liquid North Atlantic universe, ranked with a multi-measure value system and quality...
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.